The Diabetes Blood Test Strips industry trends have seen dynamic developments in the past 12–18 months, driven by strategic partnerships, mergers & acquisitions, and technological advancements. Key players like Abbott have partnered with digital health platforms to integrate real-time glucose data with mobile apps, enhancing patient engagement. In M&A activity, Medtronic’s acquisition of Diabeter in 2023 strengthened its continuous glucose monitoring (CGM) portfolio, while Roche expanded its market share through a joint venture with a diagnostics startup. Product innovations include BD’s launch of ultra-thin test strips requiring smaller blood samples and non-invasive alternatives like GlucoWise’s radar-based monitoring system entering late-stage trials. Regulatory shifts in the EU, such as updated MDR compliance requirements, have prompted manufacturers to streamline workflows and prioritize interoperability. Meanwhile, consumer demand is leaning toward pain-free, self-testing solutions, with 60% of users preferring home-based diagnostics in 2024. Funding has surged for startups leveraging AI-powered analytics and wearable tech, with firms like Dexcom securing $150M in Series D funding to scale production. These trends highlight a market increasingly focused on digital integration, user-centric design, and global accessibility, positioning the Diabetes Blood Test Strips industry for sustained growth.
